.Contending enthusiasms.R.S., M.S., H.G. and A.A.R. are actually planners of the 1M1M project.
H.G. and A.A.R. are board of directors participants as well as R.S., M.S.
and also A.A.R. are members of the clinical consultatory committee of N1C. A.A.R.
divulges job through LUMC, which has licenses on exon-skipping modern technology, a few of which has actually been actually licensed to BioMarin and ultimately sublicensed to Sarepta. As co-inventor of a few of these licenses, A.A.R. was actually qualified to a share of nobilities.
A.A.R. even further discloses functioning as ad hoc consultant for PTC Rehabs, Sarepta Rehabs, Regenxbio, Dyne Therapeutics, Lilly, BioMarin Pharmaceuticals Inc., Eisai, Entrada, Takeda, Splicesense, Galapagos, Sapreme, Italfarmaco as well as Astra Zeneca. Over the last 5 years, A.A.R.
likewise did speaking with for Alpha Anomeric. A.A.R. also reports membership of the clinical advisory boards of Eisai, Hybridize Therapies, Muteness Therapeutics, Sarepta Therapeutics, Sapreme and Mitorx.
Over the last 5 years, A.A.R. was actually also a scientific board of advisers participant for ProQR. Pay for A.A.R.
u00e2 s consulting and urging activities is paid to LUMC. Previously 5 years, LUMC also obtained speaker gratuity from PTC Therapeutics, Alnylam Netherlands, Italfarmaco and Pfizer and also cashing for contract study from Sapreme, Eisai, Galapagos, Synaffix and also Alpha Anomeric. Project backing is actually acquired from Sarepta Rehabs and also Entrada via unregulated grants.
H.G. has nothing at all to disclose in connection with the subject matters covered within this manuscript. Before 5 years, he has actually likewise acquired working as a consultant honoraria coming from UCB.
M.S. received working as a consultant gratuity from Ionis, UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly and also Solaxa previously 5 years, all unassociated to today document. R.S.
possesses absolutely nothing to make known in regard to the subjects dealt with in this particular manuscript. She has actually received audio speaker and/or consultancy honoraria or sponsoring payments from Abbvie, Bial, STADA as well as Everpharma before 5 years.